Innate Pharma Reports First Half 2023 Financial Results And Business Update
Innate Pharma announces its participation to upcoming investor conferences and conference call for First half 2023 business update
Innate Pharma to participate in upcoming investor conference
First patient dosed in SAR’514 / IPH6401 Phase 1/2 clinical trial in relapsed/refractory multiple myeloma
Number of shares and voting rights of Innate Pharma as of July 1, 2023
First patient dosed in Phase 2 MATISSE trial of IPH5201 in early stage lung cancer
Innate Pharma highlights increased lacutamab clinical activity from interim results of Phase 2 TELLOMAK study with updated Olsen criteria
Innate Pharma to present updated interim Phase 2 efficacy results of lacutamab in mycosis fungoides at the international conference on malignant lymphoma
Innate Pharma highlights proprietary tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 congress
SAR'579 / IPH6101 receives FDA Fast Track Designation in the US for the treatment of hematological malignancies
